RNASEK-C17orf49

Across TCGA pan-cancer cohorts, RNASEK-C17orf49 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RNASEK-C17orf49’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RNASEK-C17orf49 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNASEK-C17orf49 is over-expressed in tumor, although a few such as BRCA and LUAD show the opposite, repressed pattern.

STAD, LIHC, and KIRC are the cancer types where RNASEK-C17orf49 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNASEK-C17orf49 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	II,III,IV	+0.350	<.001	7	view →
LIHC	All	II,III,IV	+0.222	<.001	7	view →
KIRC	Female	All	+0.230	.001	6	view →
BRCA	All	II,III,IV	−0.122	<.001	6	view →
CHOL	Male	All	+0.586	<.001	5	view →
HNSC	All	IV	+0.204	.012	5	view →
ESCA	All	All	+0.363	<.001	3	view →
LUAD	All	All	−0.142	.002	3	view →
KICH	Female	All	−0.304	.008	2	view →
LUSC	Male	II,III,IV	−0.125	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RNASEK-C17orf49–STAD

Open the STAD breakdown →